Literature DB >> 35782622

Allan-Herndon-Dudley syndrome in a female patient and related mechanisms.

Caroline Olivati1,2, Bianca Pereira Favilla3, Erika Lopes Freitas4, Bibiana Santos4, Maria Isabel Melaragno3, Vera Ayres Meloni1,3, Flavia Piazzon1,5,6.   

Abstract

Allan-Herndon-Dudley syndrome (AHDS) is characterized by neuropsychomotor developmental delay/intellectual disability, neurological impairment with a movement disorder, and an abnormal thyroid hormone profile. This disease is an X-linked disorder that mainly affects men. We described a female patient with a de novo variant in the SLC16A2 gene, a milder AHDS phenotype, and a skewed X chromosome inactivation profile. We discuss the mechanisms associated with the expression of the phenotypic characteristics in female patients, including SLC16A2 gene variants and cytogenomic alterations, as well as preferential inactivation of the normal X chromosome.
© 2022 The Authors.

Entities:  

Keywords:  Allan-Herndon-Dudley syndrome; SLC16A2 gene; X-chromosome inactivation

Year:  2022        PMID: 35782622      PMCID: PMC9248228          DOI: 10.1016/j.ymgmr.2022.100879

Source DB:  PubMed          Journal:  Mol Genet Metab Rep        ISSN: 2214-4269


Introduction

Allan-Herndon-Dudley syndrome (AHDS, OMIM #300523) is a rare X-linked disorder, which basically affects males. It is characterized by global developmental delay and/or intellectual disability, feeding difficulties, hypotonia in infancy with poor head control, dystonia, choreoathetosis, paroxysmal movement disorder, pyramidal signs, and abnormal thyroid profile tests [1,2]. Most males have a severe intellectual disability with no speech acquisition and no development of motor milestones [1,2]. The SLC16A2 gene, located at Xq13.2, is associated with the AHDS. It encodes the MCT8 protein, a cellular transmembrane transporter specific for thyroid hormones [3], which plays an important role in neurogenesis, neuronal migration, and myelination [4]. Affected individuals show high 3,3,5′-triiodothyronine (free t3), low triiodothyronine (free and total t4), normal levels of thyroid-stimulating hormone (TSH), and a free t3/t4 ratio > 0.75, leading to peripheral hyperthyroidism, with consequent muscle wasting, high heart rate, and hypertension due to high t3 in serum. In contrast, there is central hypothyroidism because MCT8 is essential for thyroid hormones to cross the hematoencephalic barrier [4]. Although large deletions have been associated with severe encephalopathy, no genotype-phenotype association has been established [5,6]. Heterozygous female carriers of mutations in SLC16A2 are usually asymptomatic and show only abnormal laboratory thyroid tests [[7], [8], [9]], since they present a normal allele, besides the mutated one. Regarding the symptomatic carriers, the literature shows two female patients with AHDS who presented markedly skewed X-chromosome inactivation towards the allele without the variant: one due to a balanced X-9 translocation [5], and the other due to a deletion involving the SLC16A2 gene as well as the X-inactivation center [10]. Thus, investigating X-chromosome inactivation in symptomatic carriers of AHDS may also assist the genotype-phenotype correlation. We report a female patient, who shows a moderate phenotype of AHDS and heterozygous de novo missense SLC16A2 variant, and investigate her XCI pattern.

Case presentation

The 16-year-old female patient is the second child of a non-consanguineous couple with a healthy 17-year-old brother. She has attention deficit hyperactivity and an intellectual quotient (IQ) of 71 with autistic features. Her height was 1.66 m (50-85th centile), weight of 60 kg with a body mass index (BMI) of 21.8 kg/m2 (50-85th centile), span of 172 cm (6 cm above her height), and head circumference of 55 cm (+2 SD). The blood pressure was 110 × 72 mmHg, and the heart rate was 93 beats/min. She has mild dysmorphic facial features (short forehead, bitemporal narrowing, upslanted palpebral fissure, microtia I, narrow palate, and retrognathia), marfanoid habitus, joints hyperflexibility, lumbar hyperlordosis, mild thoracic scoliosis, genu recurvatum, and dry skin in both arms. The thyroid workup showed high serum levels of total-t3 and free-t3 [total-t3 220ng/dL (RV 72-214 ng/dL); free t3 0,39 ng/dL (RV 0,24–0,37 ng/dL)], with low level of free-t4 [free-t4 0,9 ng/dL (RV 1,0–1,6 ng/dL)] and normal levels of TSH [TSH 2,8 m UI/L (RV 0,50–4,9mUI/L)]. The brain magnetic resonance imaging was unremarkable.

Cytogenetic and molecular analysis

The proposita and her parents presented normal karyotypes. Whole-exome sequencing (WES) revealed a de novo rare missense variant in SLC16A2: c.1388C > T:p.Pro463Leu (ENST00000587091), confirmed by Sanger sequencing, which is absent in gnomAD and ClinVar. No deletion or duplication of the SLC16A2 gene was identified in the CNV analysis of the WES. In silico analyses support that this missense variant has a deleterious effect on protein structure or function, confirmed by a functional study [11]. The variant was classified as likely pathogenic according to the American College of Medical Genetics (ACMG – PS3, PM2, PM6, PP3). The haplotype analysis using a downstream single nucleotide polymorphism (SNP, rs5937843) revealed that the missense variant was present in the X chromosome that originated from the father (Fig. 1).
Fig. 1

Sequencing and X-inactivation results from the family. (A) At the top, idiogram of the X chromosome showing the site of the SLCA16A2 gene, at Xq13.2 (red rectangle); and at the bottom, partial result of whole-exome sequencing showing the missense variant in SLC16A2: c.1388C > T:p.Pro463Leu(ENST00000587091) on the left, and the heterozygous SNP (rs5937843), mapped at chrX:74529484 (GRCh38), 54 base pairs downstream from the SLC16A2 variant, on the right. Note that the mutated SLC16A2 allele is in cis with the G allele of the SNP. (B) Partial results of Sanger sequencing show the heterozygous SLC16A2 variant (left) in the proposita and not in her parents, and the genotypes of the upstream SNP (right). At the bottom, a schematic representation of the SLC16A2 variant plus downstream SNP haplotypes of the different members of the family reveals that the SLC16A2 variant in the proposita is on the X-chromosome received from her father. (C) Electropherogram of the HUMARA results shows allele peaks from the microsatellite polymorphic marker in the first exon of the androgen receptor (AR) gene, located at Xq11.2. The allele peaks correspond to the PCR products of samples after mock digestion (top) and after digestion with the methylation-sensitive restriction enzymes HpaII and HhaI (bottom). The proposita presents a 212-bp allele of paternal origin and a 232-bp allele of maternal origin, which is preferentially inactive (inactivation ratio:29 ± 1:71 ± 1). Her mother presented skewed inactivation towards the 226-bp allele, with the 232-bp allele being preferentially active (inactivation ratio:78 ± 1:22 ± 1).

Sequencing and X-inactivation results from the family. (A) At the top, idiogram of the X chromosome showing the site of the SLCA16A2 gene, at Xq13.2 (red rectangle); and at the bottom, partial result of whole-exome sequencing showing the missense variant in SLC16A2: c.1388C > T:p.Pro463Leu(ENST00000587091) on the left, and the heterozygous SNP (rs5937843), mapped at chrX:74529484 (GRCh38), 54 base pairs downstream from the SLC16A2 variant, on the right. Note that the mutated SLC16A2 allele is in cis with the G allele of the SNP. (B) Partial results of Sanger sequencing show the heterozygous SLC16A2 variant (left) in the proposita and not in her parents, and the genotypes of the upstream SNP (right). At the bottom, a schematic representation of the SLC16A2 variant plus downstream SNP haplotypes of the different members of the family reveals that the SLC16A2 variant in the proposita is on the X-chromosome received from her father. (C) Electropherogram of the HUMARA results shows allele peaks from the microsatellite polymorphic marker in the first exon of the androgen receptor (AR) gene, located at Xq11.2. The allele peaks correspond to the PCR products of samples after mock digestion (top) and after digestion with the methylation-sensitive restriction enzymes HpaII and HhaI (bottom). The proposita presents a 212-bp allele of paternal origin and a 232-bp allele of maternal origin, which is preferentially inactive (inactivation ratio:29 ± 1:71 ± 1). Her mother presented skewed inactivation towards the 226-bp allele, with the 232-bp allele being preferentially active (inactivation ratio:78 ± 1:22 ± 1). XCI studies by HUMARA, as described by Favilla et al. [2021] [13], revealed inactivation of the maternal and paternal alleles in the ratio of 71% and 29%, respectively, with the normal allele being preferentially inactive. Her mother presented a skewed XCI towards a different allele (78%:22%) (Fig. 1).

Discussion and conclusions

In our patient, WES revealed only one potential variant associated with developmental delay and autism. The variant is present in the coding region, leading to the Pro463Leu, which was previously associated with partial loss of thyroid hormone transport activity [11]. The same variant c.1388C > T in the SLC16A2 gene was also described in an 11-month-old male with global developmental delay, decreased muscle strength, hypotonia with severe head lag, and abnormal thyroid profile test [14]. Nonetheless, our proposita presents similar phenotypic characteristics including intellectual disability and marfanoid habitus like a man with AHDS described by Chevarin et al. [2019] [15]. Our patient has a normal karyotype, which excludes possible balanced X-autosome translocation linked to skewed X inactivation. The XCI ratio of 71%:29% in the proposita was considered undetermined [16] but leans towards a mildly skewed inactivation pattern of the maternal chromosome. The reduced percentage of active normal alleles, as the paternal chromosome, harboring the mutation, was active in approximately 71% of the cells, which also indicates altered X-inactivation as a possible mechanism for the expression of the phenotype in females. Skewed X-chromosome inactivation can be seen in the general population [17], with levels of skewing increasing with age [18], as it may have been the case for the proposita's mother. However, it is also a common feature in symptomatic carriers of X-linked mutations, favoring the expression of the mutated allele [19,20], which is the case of the proband. The female patient with AHDS previously described by Frints et al. [2008] [5] presented a balanced translocation, 46,X,t(X;9)(q13.2;p24), with disruption of the SLC16A2 gene at the breakpoint. Due to a preferential inactivation of the normal chromosome, as expected for these cases, there was no functional copy of the SLC16A2 gene, resulting in the expression of the phenotype [5]. Another symptomatic female reported by Quesada-Espinosa et al. (2021) [10] presented a de novo 543 kb deletion of the X chromosome including exon 1 of the SLC16A2 gene as well as the JPX and FTX genes. The deleted X chromosome was found to be the active one in 95% of the blood cells, which was attributed to the participation of the JPX and FTX genes in the X-chromosome inactivation. In both patients, a markedly skewed inactivation associated with cytogenetic alterations was identified, unlike the proposita described here. This suggests that there are different mechanisms underlying skewness to express the phenotype in conditions with an X-linked pattern of inheritance, even though females may not present all the most frequent characteristics of the syndrome, like our patient. The mechanisms underlying this skewed choice towards inactivating the chromosome harboring the normal allele have not been elucidated yet. It has recently been described that additional deleterious mutations on the other X-chromosome may favor the negative selection of cells in which it is expressed, generating skewed XCI and contributing to the expression of a given phenotype [19]. However, such a mechanism was not identified in the proband. Even though we did not identify an extremely skewed XCI pattern towards the normal allele for the patient in peripheral blood, we may not rule out a more skewed XCI pattern in other tissues, which could impact the expression of her phenotype. Thus, different mechanisms may be responsible for the expression of the AHDS phenotype in female patients, all of them associated with pathogenic variants in the SLC16A2 gene as well as skewed X-chromosome inactivation, which can cause milder symptoms compared to male patients.

Statement of ethics

This study protocol was reviewed and approved by the Ethics Committee of the Universidade Federal de São Paulo, approval number CAAE 40846114.2.0000.5505. Written informed consent was obtained from the patient's parents for publication of this case report and any accompanying images in compliance with the Ethics Committee of the same Institution.

Funding sources

This work was supported by (FAPESP), Brazil (grant to M.I.M. #2019/21644-0) and (CAPES).

Declaration of Competing Interest

The authors declare no conflict of interest.
  19 in total

1.  No evidence that skewing of X chromosome inactivation patterns is transmitted to offspring in humans.

Authors:  Véronique Bolduc; Pierre Chagnon; Sylvie Provost; Marie-Pierre Dubé; Claude Belisle; Marianne Gingras; Luigina Mollica; Lambert Busque
Journal:  J Clin Invest       Date:  2008-01       Impact factor: 14.808

2.  Skewed X-chromosome inactivation plays a crucial role in the onset of symptoms in carriers of Becker muscular dystrophy.

Authors:  Emanuela Viggiano; Esther Picillo; Manuela Ergoli; Alessandra Cirillo; Stefania Del Gaudio; Luisa Politano
Journal:  J Gene Med       Date:  2017-04       Impact factor: 4.565

3.  Excess of de novo variants in genes involved in chromatin remodelling in patients with marfanoid habitus and intellectual disability.

Authors:  Martin Chevarin; Yannis Duffourd; Rebecca A Barnard; Jean-Baptiste Rivière; Brian J O'Roak; Laurence Faivre; Sébastien Moutton; François Lecoquierre; Fatma Daoud; Paul Kuentz; Caroline Cabret; Julien Thevenon; Elodie Gautier; Patrick Callier; Judith St-Onge; Thibaud Jouan; Didier Lacombe; Marie Ange Delrue; Cyril Goizet; Fanny Morice-Picard; Julien Van-Gils; Arnold Munnich; Stanislas Lyonnet; Valérie Cormier-Daire; Geneviève Baujat; Muriel Holder; Florence Petit; Bruno Leheup; Sylvie Odent; Pierre-Simon Jouk; Gipsy Lopez; David Geneviève; Patrick Collignon; Dominique Martin-Coignard; Aurélia Jacquette; Laurence Perrin; Audrey Putoux; Elisabeth Sarrazin; Khadija Amarof; Isabelle Missotte; Christine Coubes; Sujatha Jagadeesh; Elisabetta Lapi; Florence Demurger; Alice Goldenberg; Martine Doco-Fenzy; Cyril Mignot; Delphine Héron; Nolwenn Jean-Marçais; Alice Masurel; Salima El Chehadeh; Nathalie Marle; Frédéric Huet; Christine Binquet; Gwenaëlle Collod-Beroud; Pauline Arnaud; Nadine Hanna; Catherine Boileau; Guillaume Jondeau; Robert Olaso; Doris Lechner; Charlotte Poe; Mirna Assoum; Virginie Carmignac; Laurence Duplomb; Frédéric Tran Mau-Them; Christophe Philippe; Antonio Vitobello; Ange-Line Bruel; Anne Boland; Jean-François Deleuze; Christel Thauvin-Robinet
Journal:  J Med Genet       Date:  2020-04-10       Impact factor: 6.318

4.  Mutations in MCT8 in patients with Allan-Herndon-Dudley-syndrome affecting its cellular distribution.

Authors:  Simone Kersseboom; Gert-Jan Kremers; Edith C H Friesema; W Edward Visser; Wim Klootwijk; Robin P Peeters; Theo J Visser
Journal:  Mol Endocrinol       Date:  2013-04-02

Review 5.  Monocarboxylate Transporters (SLC16): Function, Regulation, and Role in Health and Disease.

Authors:  Melanie A Felmlee; Robert S Jones; Vivian Rodriguez-Cruz; Kristin E Follman; Marilyn E Morris
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

6.  MCT8 mutation analysis and identification of the first female with Allan-Herndon-Dudley syndrome due to loss of MCT8 expression.

Authors:  Suzanna Gerarda Maria Frints; Steffen Lenzner; Mareike Bauters; Lars Riff Jensen; Hilde Van Esch; Vincent des Portes; Ute Moog; Merryn Victor Erik Macville; Kees van Roozendaal; Constance Theresia Rimbertha Maria Schrander-Stumpel; Andreas Tzschach; Peter Marynen; Jean-Pierre Fryns; Ben Hamel; Hans van Bokhoven; Jamel Chelly; Chérif Beldjord; Gillian Turner; Jozef Gecz; Claude Moraine; Martine Raynaud; Hans Hilger Ropers; Guy Froyen; Andreas Walter Kuss
Journal:  Eur J Hum Genet       Date:  2008-04-09       Impact factor: 4.246

7.  Disease characteristics of MCT8 deficiency: an international, retrospective, multicentre cohort study.

Authors:  Stefan Groeneweg; Ferdy S van Geest; Ayhan Abacı; Alberto Alcantud; Gautem P Ambegaonkar; Christine M Armour; Priyanka Bakhtiani; Diana Barca; Enrico S Bertini; Ingrid M van Beynum; Nicola Brunetti-Pierri; Marianna Bugiani; Marco Cappa; Gerarda Cappuccio; Barbara Castellotti; Claudia Castiglioni; Krishna Chatterjee; Irenaeus F M de Coo; Régis Coutant; Dana Craiu; Patricia Crock; Christian DeGoede; Korcan Demir; Alice Dica; Paul Dimitri; Anna Dolcetta-Capuzzo; Marjolein H G Dremmen; Rachana Dubey; Anina Enderli; Jan Fairchild; Jonathan Gallichan; Belinda George; Evelien F Gevers; Annette Hackenberg; Zita Halász; Bianka Heinrich; Tony Huynh; Anna Kłosowska; Marjo S van der Knaap; Marieke M van der Knoop; Daniel Konrad; David A Koolen; Heiko Krude; Amy Lawson-Yuen; Jan Lebl; Michaela Linder-Lucht; Cláudia F Lorea; Charles M Lourenço; Roelineke J Lunsing; Greta Lyons; Jana Malikova; Edna E Mancilla; Anne McGowan; Veronica Mericq; Felipe M Lora; Carla Moran; Katalin E Müller; Isabelle Oliver-Petit; Laura Paone; Praveen G Paul; Michel Polak; Francesco Porta; Fabiano O Poswar; Christina Reinauer; Klara Rozenkova; Tuba S Menevse; Peter Simm; Anna Simon; Yogen Singh; Marco Spada; Jet van der Spek; Milou A M Stals; Athanasia Stoupa; Gopinath M Subramanian; Davide Tonduti; Serap Turan; Corstiaan A den Uil; Joel Vanderniet; Adri van der Walt; Jean-Louis Wémeau; Jolante Wierzba; Marie-Claire Y de Wit; Nicole I Wolf; Michael Wurm; Federica Zibordi; Amnon Zung; Nitash Zwaveling-Soonawala; W Edward Visser
Journal:  Lancet Diabetes Endocrinol       Date:  2020-07       Impact factor: 32.069

8.  Spread of X-chromosome inactivation into autosomal regions in patients with unbalanced X-autosome translocations and its phenotypic effects.

Authors:  Bianca Pereira Favilla; Vera Ayres Meloni; Ana Beatriz Perez; Danilo Moretti-Ferreira; Deise Helena de Souza; Fernanda Teixeira Bellucco; Maria Isabel Melaragno
Journal:  Am J Med Genet A       Date:  2021-04-29       Impact factor: 2.802

9.  Skewed X-inactivation is common in the general female population.

Authors:  Ekaterina Shvetsova; Alina Sofronova; Ramin Monajemi; Kristina Gagalova; Harmen H M Draisma; Stefan J White; Gijs W E Santen; Susana M Chuva de Sousa Lopes; Bastiaan T Heijmans; Joyce van Meurs; Rick Jansen; Lude Franke; Szymon M Kiełbasa; Johan T den Dunnen; Peter A C 't Hoen
Journal:  Eur J Hum Genet       Date:  2018-12-14       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.